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ABSTRACT: 
Understanding the formulation features that ensure sufficient stability during long-term storage 
is critical for developing next-generation therapeutic proteins. In this work, we investigate the physical 
stability of a bispecific antibody (Bis-mAb) in 12 different formulation conditions. Isothermal chemical 
denaturation with urea indicates a higher resistance to denaturant-induced unfolding when pH is 
increased from 5.0 to 6.5 but shows minor influence from the buffer type and ionic strength. Dynamic 
and static light scattering are used to derive the interaction parameter (kD) and second virial coefficient 
(A2), respectively. These two parameters indicate that Bis-mAb exhibits highest colloidal stability in 
formulations containing 10 mM histidine buffer without added sodium chloride. Further, we observe 
that the highest relative monomer yield (RMY) after isothermal refolding, i.e. the highest refoldability, 
from urea is measured for the low ionic strength histidine formulations. Finally, we show long-term 
stability data on all 12 Bis-mAb formulations after storage at 4 and 25 °C for 12 months. The least 
amount of soluble aggregates and subvisible particles were detected in the Bis-mAb formulations with 
the highest colloidal stability and refoldability from urea. We suggest that the optimization of these two 
features is crucial for obtaining physically stable formulations of Bis-mAb.  
  
INTRODUCTION 
 Bispecific antibodies are becoming increasingly popular as therapeutic proteins because they 
can simultaneously address different antigens1,2. Such proteins are typically a result of protein 
engineering efforts and can be different from the canonical Y-shaped human IgG structure. One 
example of engineered bispecific antibodies is the IgGs with additional single-chain variable domains 
(scFvs)3. The complexity of an IgG-scFv is needed to obtain certain desired biological features3. 
However, such artificially-created protein structures can exhibit reduced physical stability and 
increased aggregation propensity during storage in comparison to naturally occurring IgGs4,5.  
The aggregation during storage of an IgG-scFv can be reduced by using suitable formulation 
conditions3,5. A set of formulations must be tested to find the optimal formulation conditions, e.g. pH 
and ionic strength, that stabilize a new protein. Such testing can be based either on lengthy and 
expensive stress and accelerated stability studies or on biophysical techniques that provide 
parameters describing protein physical stability6,7.  
The application and usefulness of short-term biophysical characterization to predict 
aggregation during storage were investigated for various proteins, e.g. cytokines8–10, IgGs11–21, dual-
viable domain IgG22 and others13,23–25. These case studies often show contradicting conclusions 
whether biophysical parameters describing protein conformational and colloidal stability can or cannot 
provide reasonable predictions for protein storage stability. These contradictions have been confusing 
for the community and led to the adoption of different philosophies about the most rational way to 
select protein formulations that will move on towards long-term stability studies. 
 Now it becomes more apparent that the optimization of specific biophysical parameters (e.g. 
melting temperature) is useful for protein development only until a mechanistic limit of a parameter is 
reached26. The mechanistic limits and weight of the different stability parameters will most probably 
differ even within the same class of proteins (e.g. IgGs), which would explain the discrepancies found 
in the literature. The considerations mentioned above open two significant questions that will be 
important for the future optimization of the protein formulation process: 1. Are there novel methods that 
can provide reasonable predictions for the aggregation of proteins during long-term storage when the 
mechanistic limits of some biophysical parameters are reached?; and 2. Which biophysical parameters 
provide truly orthogonal information, and what is the most rational set of biophysical parameters to 
predict formulations that suppress protein aggregation during storage qualitatively? 
The present work focuses on several methods for biophysical characterization that are well-
established (i.e. isothermal chemical denaturation and dynamic light scattering) or emerging (e.g. 
assessment of aggregation during refolding from a denaturant and static light scattering in multiwell 
plates) as tools to qualitatively predict the physical storage stability of proteins in different formulation 
conditions. We apply these methods to 12 formulations of a model protein, a bispecific IgG-scFv. Тhe 
latter represents a class of therapeutically relevant molecules that are rarely used in published work, 
aiming to elucidate the relationships between biophysical parameters and long-term storage stability. 
We discuss whether the measured biophysical parameters provide orthogonal information for the 
physical stability of the formulations. Finally, we also show how the stability rankings based on 
different biophysical parameters correlate with long-term stability data obtained after storage for 12 
months at 4 and 25 °C. 
MATERIALS AND METHODS 
Protein and materials 
The bispecific antibody (Bis-mAb) used in this work is a human IgG1κ-scFv. The protein 
molecular mass is 204.4 kDa, its isoelectric point is around 9. Bis-mAb was supplied at concentration 
50 mg/mL in a surfactant-free bulk buffer, which was exchanged by extensive dialysis against 10 mM 
histidine/histidine hydrochloride or 10 mM citric acid/sodium citrate buffer with pH 5.0, 5.75 or 6.5. 
Protein concentration was determined with spectrophotometry at 280 nm using a NanoDrop 2000 
(Thermo Fisher Scientific) and the respective extinction coefficient. Sodium chloride was spiked in the 
dialyzed Bis-mAb samples from stock solutions prepared with the corresponding buffers. Values for 
the ionic strength of each formulation condition are provided in Table S1.  
All chemicals were high purity grade and were purchased from Sigma Aldrich, Fisher Scientific 
or VWR International. Ultrapure water (arium® system, Sartorius Lab Instruments) was used for 
preparing all solutions. 
Isothermal chemical denaturation 
 Isothermal chemical denaturation (ICD) was performed using a previously described semi-
automated method27. Dialyzed Bis-mAb, the respective formulation buffer and 10 M urea solution in 
this buffer were combined with a Viaflo Assist system (Integra Biosciences) in 384 non-binding surface 
multiwell plates (Corning). After mixing, the samples were incubated for 24 hours at room temperature. 
Subsequently, the intrinsic protein fluorescence intensity at 330 and 350 nm was measured after 
excitation at 280 nm with a FLUOstar® Omega microplate reader (BMG Labtech). To obtain the 
isothermal chemical denaturation curves, we plotted the intrinsic protein fluorescence intensity ratio 
FI350/FI330 against the urea concentration. Origin 2018 was used to apply a Boltzmann fit to the 
curves and derive the melting denaturant concentration (C1/2) at 50 % threshold of the signal change. 
Dynamic light scattering 
 All samples were prepared by centrifugation for 10 minutes at 10,000g. Afterwards, 50 µL Bis-
mAb solution with different protein concentration in the respective formulation was filled in a Corning® 
high content imaging 384 microwell plate. The plate was centrifuged at 2200 rpm for 2 minutes using a 
Heraeus Megafuge 40 centrifuge equipped with an M-20 well plate rotor (Thermo Fisher Scientific). 
Next, each well was sealed with 10 µL silicon oil and the plate was centrifuged again as described 
above. The dynamic light scattering (DLS) measurements were performed at 25 °C with a DynaPro 
plate reader III (Wyatt Technology) and the Dynamics V7.8 software from the same company. The 
measurement of each sample consisted of 10 acquisitions of 5 s, with enabled auto-attenuation. 
Cumulant analysis was used to derive the mutual diffusion coefficient and polydispersity index from 
the autocorrelation functions. The interaction parameter kD was determined from the concentration 
dependence of the mutual diffusion coefficient using the following equation: 
 = (1 + 	) 
where D0 is the diffusion coefficient at infinite dilution and c is the protein concentration. All DLS 
measurements were performed in triplicates. 
Static light scattering 
 The samples were prepared in the same way as for DLS (see above), with the only difference 
that the wells were not sealed with silicon oil before measurements. The static light scattering (SLS) 
was measured with a DynaPro plate reader III (Wyatt Technology) operated with the Dynamics V7.8 
software. Each well was measured at 25 °C with 10 acquisitions of 3 s. The laser power was adjusted 
to 20 % and the auto-attenuation to 0 %. The respective buffers without protein were measured to 
determine the solvent offsets. The Corning® high content imaging 384 microwell plates were 
calibrated using different concentrations of a dextran standard with known molecular mass and second 
virial coefficient A2.  
 For isotropic scatterers like small proteins, the second virial coefficient can be derived from the 







where R(θ) represents the excess Rayleigh ratio of the protein solution over the solvent, c is the 
protein concentration, M is the weight-averaged protein molecular mass, A2 is the second virial 
coefficient, K is a constant (K = 4π2n0
2(dn/dc)2/(Naλ0
4), where n0 is the solvent refractive index, dn/dc is 
the protein refractive index increment, Na is the Avogadro‘s number, λ0 is the laser wavelength in 
vacuum). The calculations to derive the second virial coefficient of Bis-mAb were done with the 
Dynamics V7.8 software using a dn/dc value of 0.185 mL/g. 
Isothermal unfolding and refolding with urea (ReFOLD assay) 
 A previously presented ReFOLD assay was used to assess the effect of the formulation 
conditions on the isothermal aggregation of Bis-mAb after refolding from a denaturant30. Pierce™ 
microdialysis devices (membrane with 3.5 kDa MWCO) were used to dialyse 50 µL of formulated Bis-
mAb with 5 mg/mL concentration against 1.5 mL of 10 M urea solution prepared in the respective 
formulation buffer. The urea solution was changed 4 and 8 hours after the start. The dialysis continued 
for 24 hours. Subsequently, the same dialysis procedure was repeated against the denaturant-free 
formulation buffer. Dialysis was performed in 96 deep multiwell plates with continuous agitation at 700 
rpm using a Thermomixer Comfort (Eppendorf AG). After all dialysis steps, the samples were 
collected, each sample was weighed on a microbalance, and its weight was adjusted to 250 mg with 
the respective denaturant-free formulation buffer. The samples were centrifuged at 10,000g for 10 
minutes. The supernatant was used for analysis with size-exclusion chromatography coupled to multi-
angle light scattering (SEC-MALS). The SEC-MALS set-up consisted of a Dionex UltiMate 3000 
UHPLC system with a UV-Vis absorbance detector (Thermo Fisher Scientific), a DAWN HELEOS 
multi-angle static light scattering detector (Wyatt Technology) and a TSKgel G3000SWxl, 7.8×300 
mm, 5 µm column (Tosoh Bioscience). The running buffer had a pH of 7.0 and contained 100 mM 
potassium phosphate, 200 mM sodium chloride and 0.05 % w/v sodium azide. A flow of 0.5 mL/min 
and an injection volume of 50 µL were used. The concentration of the eluted samples was monitored 
at 280 nm. The molecular weight was calculated in the Astra v7.1 software (Wyatt Technology) from 
the UV and MALS signals using the protein extinction coefficient and the Zimm model. Chromeleon V7 
(Thermo Fisher Scientific) was used to integrate the chromatograms and calculate the monomer area 
from the UV signal. The relative monomer yield (RMY) was calculated by dividing the monomer area 
of a sample after refolding from urea by the monomer area of the sample before the refolding. 
Long-term stability study 
 Formulated Bis-mAb samples with concentration 5 mg/mL were sterile filtered using a 0.22 µm 
cellulose acetate filter and aseptically filled into sterile DIN2R glass type I vials (MGlass AG). The vials 
were crimped with FluroTec® coated rubber chlorobutyl stoppers (West Pharmaceutical Services) and 
stored at 4 and 25 °C. Three different vials were used for the analysis of each time point, formulation 
condition and storage temperature. 
 To assess the formation of small soluble aggregates during storage, we used size exclusion 
chromatography (SEC) on a Dionex Summit 2 HPLC system (Thermo Fisher Scientific). The sample 
elution was monitored at 280 nm with a UVD170U UV/Vis detector. The column and running buffer 
were the same as for the SEC-MALS method described earlier. Chromeleon V6.8 (Thermo Fisher 
Scientific) was used to integrate the chromatograms and to calculate the relative area of the 
aggregates related to the area of all protein peaks. The monomer recovery was calculated as the area 
of the monomer peak after storage was divided by the area of the monomer peak measured at the 
start of the stability study. 
 Flow imaging microscopy was employed for assessing the number and size of subvisible 
particles (SvP) formed during storage. A FlowCAM® 8100 with the VisualSpreadsheet® 4.7.6 software 
(Fluid Imaging Technologies) was used for data collection and analysis. The device was equipped with 
a 10x magnification cell (81 µm x 700 µm). The sample volume was 150 µL, the flow rate was 0.15 
mL/min, the auto image frame rate was 29 frames/second, and the sampling time was 74 seconds. 
The particle identification settings were 3 µm distance to the nearest neighbor, particle segmentation 
thresholds of 13 and 10 for the dark and light pixels respectively. The reported particle size is the 
equivalent spherical diameter (ESD).  
  
RESULTS AND DISCUSSION 
The resistance to urea-induced unfolding of Bis-mAb depends mostly on pH 
Isothermal chemical denaturation was selected to study the conformational stability of Bis-
mAb because the protein was formulated in buffers that exhibit different pH shifts during heating, thus 
complicating the rankings based on melting temperatures27. As the formulation pH is increased from 
5.0 to 6.5, higher urea concentration is needed to cause structural perturbations of Bis-mAb (Figure 1). 
The unfolding of Bis-mAb in urea is not completely reversible, and the degree of reversibility depends 
strongly on the formulation conditions (see below). Therefore, the thermodynamic analysis and 
extraction of Gibbs free energy of unfolding from the ICD curves would be inaccurate31. A further 
complication for the analysis is that Bis-mAb does not exhibit clearly defined transitions that can be 
well described by a two-state or a three-state unfolding model (data not shown). For these reasons, 
we fitted the obtained ICD curves using a Boltzmann function and derived denaturant melting 
concentrations (C1/2) that indicate the resistance to urea-induced unfolding in different formulation 
conditions (Figure 1). Similar approaches that employ ICD to determine relative C1/2 values are shown 
to be predictive for the storage stability of some proteins32. The differences in the C1/2 between 
conditions, i.e. different buffers and ionic strengths, with the same pH are only minimal, within 0.1-0.2 
M urea (Table 1). In comparison, pH has a much larger effect on the C1/2 of Bis-mAb – an increase in 
pH from 5.0 to 6.5 shifts the C1/2 by approximately 0.6-0.7 M in both histidine- and citrate-based 
formulations, regardless of the ionic strength. 
The colloidal stability of Bis-mAb depends on the buffer type and addition of sodium chloride 
The mutual diffusion coefficient of Bis-mAb was determined at different protein concentrations 
and in different formulation conditions (Figure 2). In formulations with 10 mM histidine buffer without 
added sodium chloride, the D0 increases with increasing protein concentration regardless of the pH 
(Figure 2a). In all other formulation conditions, the mutual diffusion coefficient decreases with 
increasing Bis-mAb concentration. Correspondingly, the interaction parameter kD is highest in the low 
ionic strength histidine formulations and negative in all other conditions (Table 1). The high kD can be 
attributed to strong electrostatic repulsion between the monomers. The formulations containing 10 mM 
citrate without added sodium chloride also have relatively low ionic strength but exhibit much lower kD 
compared to histidine counterparts. These effects can be explained by the binding of the citrate ion to 
the protein that inverts protein surface charge and diminishes the electrostatic repulsion33,34. The 
addition of 70 mM NaCl levels out the differences in kD of Bis-mAb in the two different buffers (see 
Figure 2) due to screening of the electrostatic interactions35. 
 The static light scatting results closely resemble the dynamic light scattering data (Figure 3). 
The second virial coefficient A2 of Bis-mAb is highest in the 10 mM histidine formulations without 
added salt (Figure 3a and Table 1). In all other conditions, A2 is significantly lower, but contrary to kD 
does not reach negative values upon screening of the electrostatic repulsion (Table 1). Both the good 
correlation and the offset between A2 and kD are well known for monoclonal antibodies and the 
reasons for them have been elucidated35,36. This agreement between kD and A2 is also valid for the 
formulations of the bispecific antibody used in this work. 
The formulation conditions affect Bis-mAb aggregation during refolding from urea 
The freshly prepared Bis-mAb formulations contain more than 95 % monomer and a fraction of 
dimer in all 12 conditions (see below). After isothermal refolding from urea, a significant amount of the 
protein monomer is lost and aggregates of various sizes from dimer to multimers can be detected with 
SEC-MALS (Figure 4a). The highest relative monomer yield, i.e. highest refoldability, is detected in 10 
mM histidine formulations without additional NaCl (Figure 4b). This indicates that the least amount of 
Bis-mAb monomer aggregates through non-native interactions in these three conditions. Formulations 
containing 10 mM citrate buffer or 70 mM sodium chloride show dramatically lower relative monomer 
yield (Figure 4b), indicating the high aggregation propensity of the (partially) unfolded Bis-mAb in 
these conditions. Noteworthy, Bis-mAb has lower much lower RMYs compared to three IgGs that were 
studied at similar protein concentration in the same formulation conditions, indicating that this 
bispecific antibody is very prone to aggregation during refolding30,37. Whether bispecifics have lower 
refoldability compared to analogical antibodies with canonical IgG structure is yet to be investigated. 
Bis-mAb forms soluble aggregates and subvisible particles during long-term storage 
 The long-term stability studies were performed for 12 months at 4 and 25 °C. At the 
designated sampling points, the relative area of aggregates was assessed with size exclusion 
chromatography (Figure 5). Bis-mAb formulations already contain slightly different amount of 
aggregates at the beginning of the stability study, which indicates that the formulation conditions have 
an impact on the self-association of the protein that is quickly evident within the timeframe between 
sample preparation and SEC analysis (less than 5 days at 4 °C). The smallest change in the relative 
area of aggregates was observed for the 10 mM histidine formulations, regardless of the pH, during 
storage at 4 and 25 °C (Figure 5a and 5b). In all other cases, the relative aggregate area increased 
more during long-term storage. Interestingly, Bis-mAb formed an almost similar amount of aggregates 
during storage at 4 and 25 °C, which might be due to protein aggregation that follows non-Arrhenius 
behaviour38. In the present work, we do not have enough experimental data to calculate aggregation 
rates at different temperatures accurately to confirm this theory. However, non-Arrhenius aggregation 
is typical for folded monomeric proteins (like Bis-mAb), and a concave up lnk versus 1/T dependence 
can explain similar aggregation rates at 4 and 25 °C. More information about the reasons of non-
Arrhenius protein aggregation behaviour can be found in the literature38–41. 
 Considerable numbers of subvisible particles were formed during storage in most Bis-mAb 
formulations (Figure 6). The lowest numbers of SvP were detected in the 10 mM histidine formulations 
with low ionic strength (Figure 6a). In general, there is a trend that the formulations that contain 70 mM 
NaCl formed more subvisible particles (Figure 6c, 6d, 6g and 6h) compared to counterparts with lower 
ionic strength (Figure 6a, 6b, 6e and 6f). These observations are in accordance with the effect of ionic 
strength on the aggregate size formed by other proteins when the electrostatic repulsion between 
monomers is screened42.  
 In general, Bis-mAb forms more soluble aggregates and subvisible particles during long-term 
storage compared to two IgGs that we studied at similar formulation and storage conditions30. This 
observation concurs well with the lower RMYs of the bispecific antibody compared to the IgGs from 
previous work. Although the currently published data is limited to make conclusions in this direction, it 
seems that less physically stable proteins could have lower refoldability. Therefore, future studies 
should focus on the importance of refoldability for the selection of developable protein drug 
candidates. 
Colloidal stability and refoldability correlate with Bis-mAb aggregation during storage 
 Looking for connections between biophysical parameters (measured in short timeframes) and 
the information obtained during long-term stability studies at 4 and 25 °C, we compared some of the 
values presented above. We depicted both linear correlations with their 95 % confidence ellipses and 
Spearman`s rank correlation coefficients (R) between the mean values of biophysical parameters and 
long-term stability data obtained for the formulations (Figure 7).  
The strongest correlation between biophysical parameters that we observe is between kD and 
A2 (Figure 7), which is already reported for other proteins
35,36. Interestingly, the R between kD (or A2) 
and the relative monomer yield from the ReFOLD assay is below the threshold for significance. 
Although all these three parameters indicate high physical stability of Bis-mAb in the 10 mM histidine 
formulations without NaCl, the exact stability ranking based on kD (or A2) and the RMY is different. 
There is also a strong correlation between D0 and Mm (Figure 7) which appears logical as both 
parameters will be affected by the presence of a small aggregate population that was detected in all 
samples with size exclusion chromatography.  
When we compare the biophysical parameters that can be assessed in short timeframes to 
the long-term stability studies, we observe several significant rank correlations. First, the interaction 
parameter kD and the second virial coefficient A2 correlate with the relative area of aggregates formed 
after 12 months of storage at 4 and 25 °C (Figure 7). Second, the RMY from the ReFOLD assay 
shows very strong rank correlation with the relative area of aggregates and the monomer loss after 12 
months at 25 °C (Figure 7). There is also a moderate correlation between RMY and the monomer loss 
at 4 °C (the rank correlation between RMY and the relative area of aggregates at 4 °C is just below the 
threshold to be considered significant). And third, the melting denaturant concentration C1/2 correlates 
significantly only with the monomer loss after storage at 25 °C (Figure 7).  
We also observe several significant ranking correlations between long-term stability data. For 
example, the rankings for aggregates, monomer loss and subvisible particles obtained after storage at 
25 °C correlate well with the rankings based on these parameters measured after storage at 4 °C. 
These findings support a recent publication that discusses the practicality of accelerated stability 
studies at different temperatures to predict protein aggregation during long-term storage under 
refrigerated conditions43. 
An interesting observation is that the diffusion coefficient at infinite dilution D0 was the only 
biophysical parameter that shows a significant correlation with the number of subvisible particles 
(Figure 7). A possible explanation here might be that some of the soluble aggregates in samples prone 
to form subvisible particles were quickly depleted by forming larger aggregates. The latter were then 
removed during the centrifugation step before the DLS analysis. This will result in a larger fraction of 
soluble aggregates, respectively lower D0, in formulation conditions where the formation of SvP is 
suppressed.  
 Although it is interesting to look into the linear and rank correlations between the parameters, 
we should underline that the formulations of Bis-mAb that exhibited the lowest aggregation and SvP 
formation during storage, were clearly the formulations that have significantly higher colloidal stability 
(based on kD and A2 values) and refoldability (based on RMY after refolding from urea) (see Table 1). 
In contrast, formulations with higher C1/2 values did not exhibit better storage stability in most cases. 
This indicates that the C1/2 values of all 12 Bis-mAb formulations are most probably already above the 
mechanistic limit of this parameter. Thus, making C1/2 not predictive for the aggregation during long-
term storage of these formulations. 
Refoldability and colloidal stability studies provide orthogonal information 
We previously showed that assessing the aggregation during dilution- or dialysis-refolding 
from denaturants can be a valuable tool to select monoclonal antibody formulations with higher 
physical stability and suppressed aggregation during storage30,37,44. In an effort to standardize such 
experiments, we presented a ReFOLD assay that is based on microdialysis in deep multiwell plates30. 
We demonstrated that assessing the effect of the formulation on the protein monomer yield (i.e. the 
fraction of monomer that is not aggregated after unfolding and refolding with urea) from the ReFOLD 
assay is a valuable approach to qualitatively predict the physical storage stability of three different 
antibodies in various formulation conditions30,37. In the study presented here, we applied this concept 
to a different molecule – the bispecific antibody Bis-mAb which is a human IgG1κ-scFv protein. We 
found that the formulation conditions that lead to the highest relative monomer yield after refolding 
from urea are the formulations that impede aggregation and subvisible particle formation of Bis-mAb 
during long-term storage for 12 months at 4 and 25 °C.  
The aggregation after refolding from denaturants of some proteins is related to parameters 
describing the colloidal protein stability in the presence in denaturants45,46. In our work, we also 
focused on two widely used parameters that describe the protein-protein interactions in solution45,46. 
We found that Bis-mAb formulations that have significantly higher second virial coefficient A2 and 
interaction parameter kD in the absence of denaturants are the formulations that have the highest 
relative monomer yield after refolding from urea. However, there was no significant rank correlation 
between kD (or A2) and the RMY, indicating that although these biophysical parameters are connected, 
they carry different and complementary information. We also recently reported a similar interplay 
between kD, A2 and RMY for an IgG antibody
37.  
The colloidal stability of the native state is undoubtedly crucial for obtaining formulations with 
suppressed aggregation during storage. However, the effect of the formulation on the aggregation 
propensity of the partially unfolded protein at ambient temperatures also seems to play an important 
role for several IgGs and in this case for a bispecific antibody. This aggregation propensity can be 
quickly assessed by using an unfolding/refolding experimental setup like the ReFOLD assay, or by 
measuring the second virial coefficient or the aggregation of a protein in the presence of 
denaturants45,47,48. Such experiments with denaturants offer several advantages over traditional 
thermal denaturation methods, as they do not require sample heating and result in more moderate 
aggregation of the partially unfolded protein that allows comparisons between the effect of the 
formulation on the non-native protein aggregation27,30. Currently, we are limited by the fact that we 
cannot observe the unfolding/refolding and aggregate formation in the dialysis device as the 
denaturant concentration is changed. To this end, we are focusing on experimental setups that allow 
automated microdialysis with in situ detection of protein conformational changes and aggregation. We 
believe that such setups will provide a better understanding of the concept behind the ReFOLD assay. 
CONCLUSIONS 
In this work, we applied several methods to study the physical stability of a bispecific antibody 
in 12 formulation conditions. In addition, we performed long-term stability studies for 12 months at 4 
and 25 °C to investigate whether some of the assessed biophysical parameters can provide qualitative 
predictions for the aggregation of Bis-mAb in different formulations. We observe a strong correlation 
between A2 and kD, but no significant rank correlation between either of these two parameters and the 
relative monomer yield after refolding from urea. These findings suggest that assessing the colloidal 
stability of the native protein and studying the aggregation during refolding from denaturants are two 
orthogonal approaches. Both of the latter show reasonable predictions for the ranking of Bis-mAb 
formulations in order of their effect on protein aggregation during long-term storage. These findings 
add to our earlier reports with formulations of three IgGs30,37, further supporting the hypothesis that the 
high reversibility of isothermal protein unfolding (induced by denaturants like urea) is a key feature of 
physically stable formulations of therapeutic proteins. 
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Figure 1.Isothermal chemical denaturation curves of Bis-mAb at pH 5.0 (green squares), pH 5.75 (yellow circles) 
and pH 6.5 (red triangles) in (a) 10 mM histidine buffer without NaCl, (b) 10 mM histidine buffer with 70 mM NaCl, 
(c) 10 mM citrate buffer without NaCl and (d) 10 mM citrate buffer with 70 mM NaCl. Bis-mAb concentration is 0.5 
mg/mL. The values are mean of triplicates, and the error is the standard deviation. The lines are a Boltzmann fit. 
The inset shows the residuals from the fit. 
Figure 2. Effect of the formulation condition on the mutual diffusion coefficient of Bis-mAb at different protein 
concentrations -  pH 5.0 (green squares), pH 5.75 (yellow circles) and pH 6.5 (red triangles) in (a) 10 mM histidine 
buffer without NaCl, (b) 10 mM histidine buffer with 70 mM NaCl, (c) 10 mM citrate buffer without NaCl and (d) 10 
mM citrate buffer with 70 mM NaCl. The values are mean of triplicates, and the error is the standard deviation. 
The lines are linear fit to the data. 
Figure 3. Effect of the formulation condition on the (Kc/(R(θ)) of Bis-mAb at different protein concentrations -  pH 
5.0 (green squares), pH 5.75 (yellow circles) and pH 6.5 (red triangles) in (a) 10 mM histidine buffer without NaCl, 
(b) 10 mM histidine buffer with 70 mM NaCl, (c) 10 mM citrate buffer without NaCl and (d) 10 mM citrate buffer 
with 70 mM NaCl. The values are mean of triplicates, and the error is the standard deviation. The lines are linear 
fit to the data. 
Figure 4. a - SEC-MALS chromatogram of Bis-mAb before unfolding with urea (green triangles) and after 
isothermal refolding from urea (red squares); b – Effect of the formulation conditions on the relative monomer 
yield of Bis-mAb after isothermal refolding from urea; 
Figure 5. Effect of the formulation conditions on the relative area of aggregates of Bis-mAb detected with size 
exclusion chromatography during storage at 4 °C (left column) and 25 °C (right column). Formulations with  pH 
5.0 (green squares), pH 5.75 (yellow circles) and pH 6.5 (red triangles) in (a, b) 10 mM histidine buffer without 
NaCl, (c, d) 10 mM histidine buffer with 70 mM NaCl, (e, f) 10 mM citrate buffer without NaCl and (g, h) 10 mM 
citrate buffer with 70 mM NaCl. The values are mean of triplicates, and the error is the standard deviation. The 
lines are guides for the eyes. 
Figure 6. Effect of the formulation conditions on the cumulative number of subvisible particles ≥ 2 µm per mL of 
Bis-mAb detected with flow imaging microscopy during storage at 4 °C (left column) and 25 °C (right column). 
Formulations with  pH 5.0 (green squares), pH 5.75 (yellow circles) and pH 6.5 (red triangles) in (a, b) 10 mM 
histidine buffer without NaCl, (c, d) 10 mM histidine buffer with 70 mM NaCl, (e, f) 10 mM citrate buffer without 
NaCl and (g, h) 10 mM citrate buffer with 70 mM NaCl. The values are mean of triplicates, and the error is the 
standard deviation. The lines are guides for the eyes. 
Figure 7. Correlation between biophysical parameters of Bis-mAb (grouped in the blue square) and long-term 
stability data (grouped in the red square). The “% aggr. 25 °C” and the “% aggr. 4 °C” represent the relative area 
of aggregates from size exclusion chromatography detected after 12-month storage. The “% mon. 25 °C” and “% 
mon. 4 °C” represent the monomer recovery after 12-month storage. The “SvP 25 °C” and “SvP 4 °C” are the 
cumulative number of particles after 12 months of storage at the respective temperatures. The correlations are 
tested between the mean values of triplicates. The red lines are linear fits to the data, the red ellipses are the 
confidence ellipses at 95 % level. The empty squares for the Spearman`s rank correlation coefficient are cases 
where the rank correlation was not significant (p>0.05). 
Table 1. Biophysical parameters of Bis-mAb in different formulation conditions - melting denaturant concentration 
C1/2 from isothermal chemical denaturation; second virial coefficient A2 and molecular mass Mm from static light 
scattering; interaction parameter kD and diffusion coefficient at infinite dilution D0 from dynamic light scattering; 
















histidine 5.0 0 5.43 (±0.03) 2.81 (±0.08) 230 (±3.05) 3.407 (±0.26) 3.61 (±0.03) 
0.295 
(±0.008) 
histidine 5.75 0 5.85 (± 0.02) 2.51 (±0.15) 230 (±5.71) 3.21 (±0.08) 3.63 (±0.01) 
0.271 
(±0.009) 
histidine 6.5 0 6.16 (±0.01) 3.65 (±0.24) 232 (±7.85) 7.03 (±0.10) 3.55 (±0.01) 
0.237 
(±0.011) 
histidine 5.0 70 5.32 (±0.07) 1.18 (±0.10) 231 (±4.71) -0.347 (±0.17) 3.71 (±0.03) 
0.029 
(±0.003) 
histidine 5.75 70 5.67 (±0.02) 0.67 (±0.05) 216 (±2.24) -1.015 (±0.16) 3.77 (±0.03) 
0.055 
(±0.003) 
histidine 6.5 70 5.96 (±0.03) 0.60 (±0.12) 226 (±5.70) -1.393 (±0.20) 3.74 (±0.03) 
0.058 
(±0.002) 
citrate 5.0 0 5.39 (±0.01) 1.06 (±0.14) 222 (±2.78)  -0.775 (±0.06) 3.83 (±0.02) 
0.008 
(±0.002) 
citrate 5.75 0 5.81 (±0.02) 0.72 (±0.03) 213 (±1.74) -0.908 (±0.14) 3.84 (±0.02) 
0.020 
(±0.004) 
citrate 6.5 0 6.07 (±0.01) 0.56 (±0.01) 211 (±0.39)  -1.167 (±0.04) 3.87 (±0.01) 
0.029 
(±0.005) 
citrate 5.0 70 5.29 (±0.04) 0.98 (±0.07) 229 (±2.90) -0.748 (±0.03) 3.69 (±0.01) 
0.005 
(±0.001) 
citrate 5.75 70 5.70 (±0.03) 0.76 (±0.05) 218 (±2.32) -1.023 (±0.11) 3.76 (±0.04) 
0.024 
(±0.002) 
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